![]() |
![]() |
J Acupunct Res > Volume 39(3); 2022 > Article |
|
Certainty assessment | No. of patients | Effect | Certainty | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
No of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | EA | control | Relative (95% CI) | Absolute (95% CI) | |
Fatigue | |||||||||||
|
|||||||||||
5 | Randomized trials | Serious*,†,‡ | Serious§; | Not serious | Not serious | None | 141 | 157 | - | SMD 1.54 lower (2.57 lower to 0.52 lower) | ⊝⊝○○ Low |
|
|||||||||||
Fatigue - EA vs Acu (FSS) | |||||||||||
|
|||||||||||
2 | Randomized trials | Very serious*,†,‡ | Not serious | Not serious | Not serious | None | 76 | 93 | - | SMD 1.99 lower (4.26 lower to 0.28 higher) | ⊝○○○ Very Low, || |
|
|||||||||||
Fatigue - EA vs sham EA (FSS) | |||||||||||
|
|||||||||||
2 | Randomized trials | Serious†,‡ | Not serious | Not serious | Not serious | None | 35 | 34 | - | SMD 1.54 lower (2.97 lower to 0.1 lower) | ⊝⊝○○ Low, || |
|
|||||||||||
Fatigue - EA+H-med vs H-med (FAI) | |||||||||||
|
|||||||||||
1 | Randomized trials | Serious†,‡ | Not serious | Not serious | Not serious | None | 30 | 30 | - | SMD 0.74 lower (1.27 lower to 0.22 lower) | ⊝⊝○○ Low, || |
Certainty assessment | No of patients | Effect | Certainty | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
No of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | EA | control | Relative (95% CI) | Absolute (95% CI) | |
QoL | |||||||||||
|
|||||||||||
6 | Randomized trials | Serious*,†,‡ | Serious§ | Not serious | Not serious | None | 176 | 172 | - | SMD 2.29 lower (3.67 lower to 0.9 lower) | ⊝⊝○○ Low |
|
|||||||||||
QoL - EA vs Acu (SPHERE) | |||||||||||
|
|||||||||||
3 | Randomized trials | Very serious*,†,‡ | Not serious | Not serious | Not serious | None | 111 | 108 | - | SMD 3.39 lower (6.38 lower to 0.41 lower) | ⊝○○○ Verylow, || |
|
|||||||||||
QoL - EA vs Sham EA (SPHERE) | |||||||||||
|
|||||||||||
2 | Randomized trials | Serious†,‡ | Not serious | Not serious | Not serious | None | 35 | 34 | - | SMD 1.3 lower (2.88 lower to 0.28 higher) | ⊝⊝○○ Low, || |
|
|||||||||||
QoL - EA+H-med vs H-med (WHOQOL-BREF) | |||||||||||
|
|||||||||||
1 | Randomized trials | Serious†,‡ | Not serious | Not serious | Not serious | None | 30 | 30 | - | SMD 1.15 lower (1.7 lower to 0.6 lower) | ⊝⊝○○ Low, || |
Author (year) | Sample size (included ->analyzed) | TG fender and mean age (mean±SD) | TG disease duration (mo) (mean± SD) | Treatment intervention | Control intervention | Outcome measure | Result* | Adverse event |
---|---|---|---|---|---|---|---|---|
Diagnosis | CG gender and mean age (mean±SD) | CG disease duration (mo) (mean± SD) | ||||||
EA VS Conventional Acupuncture | ||||||||
|
||||||||
Li (2017) [14] | 89 (46/43→46/43) |
M/F = 18/28 39 ± 10 |
13.6 ± 6.9 | EA | Acupuncture |
1) FSS 2) SPHERE |
(T/C, Baseline, 4 wk) 1) 40.41 ± 3.61→24.41 ± 3.62 (p < 0.001)/39.02 ± 5.28→38.14 ± 4.78 (p < 0.001) 2) 25.96 ± 2.76→12.74 ± 2.27 (p < 0.001)/25.07 ± 2.44→24.19 ± 1.06 (p < 0.001) |
None |
1994 CDC |
M/F = 17/26 38±9 |
14.0 ± 6.6 | ||||||
|
||||||||
Chen (2018) [15] | 60 (30/30) |
M/F = 11/19 45.03 ± 5.12 |
22.36 ± 7.02 | EA | Cat gut Acupuncture |
1) FSS 2) SPHERE 3) TER |
(T/C, Baseline, 4 wk) 1) 51.70 ± 11.37→35.07 ± 7.54 (p >0.05)/52.73 ± 11.75→41.15 ± 6.87 (p > 0.05) 2) 34.54 ± 4.11→10.55 ± 2.41 (p > 0.05)/35.22 ± 4.85→12.36 ± 2.63 (p > 0.05) 3) 90.00%/86.67% (p > 0.05) |
Not reported |
1994 CDC |
M/F = 10/20 44.68 ± 5.23 |
23.12 ± 6.89 | ||||||
|
||||||||
Li (2014) [16] | 60 (30/30→30/30) |
Not disclosed (25–50) |
Not disclosed (at least 7 mo) |
EA | Acupuncture | 1) TER |
(T/C, Baseline, 10d) 1) 93.33%/83.33% (p < 0.5) |
Not reported |
1994 CDC |
Not disclosed (25–50) |
Not disclosed (at least 7 mo) |
||||||
|
||||||||
Zhang (2019) [17] | 70 (35/35→35/35) |
M/F = 17/18 38.22±9.25 |
11.94 ± 5.19 | EA+Mox | Acupuncture+W-med |
1) FS-14 2) SPHERE 3) PSQI 4) IL-6 5) IFN-γ |
(T/C, Baseline, 4wk) 1) 5.72 ± 0.91→1.57 ± 0.42 (p < 0.05)/5.85 ± 0.83→3.34 ± 0.47 (p < 0.05; physical) 4.97 ± 0.77→1.24 ± 0.32 (p < 0.05)/4.56 ± 0.69→2.34 ± 0.41 (p < 0.05; mental) 2) 25.45 ± 5.22→9.02 ± 1.95 (p < 0.05)/24.86 ± 5.49→16.69 ± 2.69 (p < 0.05) 3) 17.22 ± 3.21→5.05 ± 1.83 (p < 0.05)/16.89 ± 3.97→10.76 ± 2.09 (p < 0.05) 4) 45.61 ± 5.91→25.57 ± 4.19 (p < 0.05)/46.88 ± 6.02→36.34 ± 4.40 (p < 0.05) 5) 49.98 ± 5.77→27.20 ± 3.82 (p < 0.05)/46.88 ± 6.02→37.52 ± 4.43 (p < 0.05) |
Not reported |
1994 CDC |
M/F = 16/19 37.56 ± 9.91 |
37.56 ± 9.91 | ||||||
|
||||||||
EA VS non-acu point electric stimulation | ||||||||
|
||||||||
Zhu (2008) [18] | 60 (30/30->30/28) |
M/F = 6/24 38.50 ± 7.89 |
15.30 ± 5.72 | EA | Non-acu point electric stimulation |
1) FSS 2) SPHERE 3) VAS |
(T/C, Baseline, 3 mo) 1) 46.93 ± 5.65→25.60 ± 5.06 (p < 0.001)/45.77 ± 5.35→38.47 ± 6.64 (p < 0.001) 2) 19.77 ± 3.35→7.83 ± 2.84 (p < 0.001)/19.47 ± 2.89→14.77 ± 3.92 (p < 0.001) 3) 59.33 ± 14.13→ 31.00 ± 10.62 (p < 0.01)/56.67 ± 11.55→ 42.33 ± 10.06 (p < 0.01) |
Not reported |
1994 CDC |
M/F = 10/20 37.67 ± 9.85 |
16.70 ± 5.43 | ||||||
|
||||||||
EA VS non-acu point electric stimulation | ||||||||
|
||||||||
Oh (2006) [19] | 9 (5/4→5/4) |
M/F = 1/4 36.60 ± 6.84 |
Not disclosed (at least 7 mo) |
EA | Non-acu point electric stimulation |
1) FSS 2) SPHERE |
(T/C, Baseline, 3 mo) 1) 50.20 ± 8.82→31.00 ± 9.62 (p <0.05)/44.75 ± 10.34→40.00 ± 14.78 (p <0.05) 2) 21.00 ± 3.08→13.60 ± 9.29 (p <0.05)/19.00 ± 4.54→16.75 ± 3.86 (p < 0.05) |
Not reported |
1994 CDC |
M/F = 6/24 35.75 ± 5.12 |
Not disclosed (at least 7 mo) |
||||||
|
||||||||
EA VS Conventional treatment | ||||||||
|
||||||||
Hu (2013) [20] | 60 (30/30→30/30) |
M/F = 12/18 37.36 ± 8.55 |
38.27 ± 8.73 | EA+H-med | H-med |
1) FAI 2) WHOQOL-BREF |
(T/C, Baseline, 10 days) 1) 145.53 ± 9.96→78.67 ± 9.52 (p < 0.01)/147.37 ± 8.37→86.33 ± 10.78 (p < 0.01) 2) 78.03 ± 8.62→99.77 ± 7.86 (p < 0.01)/75.80 ± 9.56→84.57 ± 16.74 (p < 0.01) |
10 bleeding |
1994 CDC |
M/F = 13/17 37.20 ± 6.93 |
39.30 ± 7.55 |
C, control; CDC, Centers for Disease Control and Prevention; CG, control group; F, female; FS-14, fatigue scale-14; FSS, fatigue severity scale; H-med, herbal medicine; M, male; PSQI, Pittsburgh Sleep Quality Index; SPHERE, The Somatic and Psychological Health Report-34 items; T, treatment; TER, total effective rate; TG, treatment group; VAS, visual analogue scale; WHOQOL-BREF, WHO Quality of Life-BREF; W-med, Western medicine.
Author (year) | Treatment period | Treatment Frequency | Acupoint | Details of needling | Details of EA | Needle retaining time |
---|---|---|---|---|---|---|
Li (2017) [14] | 4 wk | 5 x/wk | GV 14, GV 4, CV 8, CV 4 | Insert needle until de qi | Fre 100/2 Hz 14±2 mA | 30 min |
Chen (2018) [15] | 4 wk | 2 x/wk | CV17, CV6, CV4, ST36, BL13, BL18, BL20, BL23, Select 10 points at a time from the above acupoints | 1~1.5 cun needle, insert needle until de qi |
Fre: 3Hz Int: according to the patient’s tolerance level |
30 min |
Li (2014) [16] | 10 d | 1 x/3 d | CV4, ST36, PC6, EX-HN 5 BL23 (if have insomnia), GB34 (if pain at muscle) | 0.30 x 0.40 needle, insert needle until de qi | Int: according to the patient’s tolerance level | 30 min |
Zhong (2019) [17] | 4 wk | 1 x/d | CV8 (EA), TE17 (EA) | TE17: insert 15 mm parallel to ear canal | Int: according to the patient’s tolerance level | 30 min |
Zhu (2008) [18] | 12 d | 10 x/12 d | ST36 (EA), BL23 (EA) | 1~1.5 cun needle, insert needle until de qi |
Fre: 4/20Hz Int: according to the patient’s tolerance level |
20 min |
Oh (2006) [19] | 10 d | 1 x/d | ST36 (EA), BL23 (EA) | 2 cun needle, insert needle until de qi |
Fre: 20–100Hz Int: according to the patient’s tolerance level |
20 min |
Hu (2013) [20] | 4 wk | 3 x/wk | 1) CV 4, EX-HN 1 BL15, BL17, BL18, BL20, 2) GV 4, CV 6, CV 4, ST 36, LI 4, LR3 Select 1) or 2) | 1~1.5 cun needle, insert needle until de qi | Int: according to the patient’s tolerance level | 30 min |
![]() |
![]() |